TO THE EDITOR:
Thank you Deborah Harris for illuminating, in the article from Sept. 2, “UNC’s technology licensing revenue doubles,” the indispensable work the Office of Technology Development does to create financial value for UNC.
Although we are a world-renowned research institution, laboratory breakthroughs and innovative products are little more than ideas without the regulatory and business development guidance that OTD provides.
In her article, Harris mentions the substantial payday Sarepta Therapeutics and Epizyme provided the University last year.
What’s even more impressive is, these companies, both publicly traded and each with a market cap around $1 billion, can trace much of their clinical pipeline back to UNC and the Office of Technology Development.
Tanner Beam ’11
Biology
